GP Portal now available to all ICBs! Learn more

MHRA Drug Safety update: Pregabalin (Lyrica): reports of severe respiratory depression

Pregabalin has been associated with reports of respiratory depression, in some cases without concomitant opioid treatment.
Healthcare professionals are advised to consider whether adjustments in dose or dosing regimen are necessary for patients at higher risk of respiratory
depression, this includes people:

  • with compromised respiratory function, respiratory or neurological disease, or
    renal impairment
  • taking other CNS depressants (including opioid-containing medicines)
  • aged older than 65 years